It was our pleasure to welcome investors to Madison last week. We're confident that all in attendance left with a better understanding of TomoTherapy's competitive advantage and belief in our distinct technological edge in meeting the radiotherapy needs of clinicians and their patients, today and for years to come.
MADISON, Wis. (PRWEB) March 20, 2008
Dr. Kupelian, director of clinical research for radiation oncology at MD Anderson Cancer Center Orlando, spoke on his early adoption of the Hi-Art treatment system and the center's recent decision to purchase a second Hi-Art unit.
"Early on, we saw TomoTherapy as an innovative tool in the fight against cancer. We recognized the benefit of integrating treatment capabilities onto an imaging device, rather than simply adding imaging to a treatment platform that wasn't originally designed for image guidance," said Dr. Kupelian. "Now, it's difficult to see how we ever performed radiotherapy without effective image guidance. Our staff values the confidence that comes with daily CT imaging of patients."
Dr. Kupelian added: "With the second TomoTherapy unit, we will be able to expand our offerings in image-guided, intensity-modulated radiation therapy (IG-IMRT). Furthermore, we can pursue new opportunities that TomoTherapy makes possible, such as online adaptive radiotherapy and the delivery of higher doses of radiation over a shorter period of time."
Dr. Ramsey, director of medical physics at Thompson Cancer Survival Center in Knoxville, Tenn., presented his experience with various forms of rotational radiation therapy.
Said Dr. Ramsey: "In July 2003, our center became the first to treat patients with a commercial TomoTherapy device. Since then we've used it to treat well over 1,000 people, each with superior dose distributions and CT imaging prior to their treatment sessions. There's no doubt that Hi-Art is the right platform for rotational radiation therapy, because it consistently delivers a uniform dose to the target volume. I say that with confidence as a current user of both TomoTherapy and Varian Medical Systems equipment, and as an active researcher attempting to make single-rotation volumetric modulated arc therapy (VMAT) a viable option on conventional linear accelerators."
Notable presentations from TomoTherapy's management team included:
-- Co-founder and chairman of the board Rock Mackie, Ph.D., detailing the Hi-Art treatment system's unique CT-based design and helical delivery of IMRT;
-- Paul Baumgart, director of international distribution, on strengthening TomoTherapy's sales organization; and
-- Don Parnell, former clinical user of the Hi-Art treatment system and current market development manager for TomoTherapy, highlighting emerging clinical evidence of the system's ability to help reduce side effects and improve outcomes in cancer treatment.
Said Fred Robertson, CEO of TomoTherapy: "It was our pleasure to welcome investors to Madison last week. We're confident that all in attendance left with a better understanding of TomoTherapy's competitive advantage and belief in our distinct technological edge in meeting the radiotherapy needs of clinicians and their patients, today and for years to come."
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy(R) Hi-Art(R) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
(C)2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.